Appendix 4E and Preliminary Final Report

Key points

• Revenue from contracts with customers decreased by 23.8% to $2,767,888
• Loss from ordinary activities after tax increased by 50.3% to $(55,149,150)
• Net assets decreased to $22,323,683 due to higher R&D expenditures
• Increased ownership in Radiopharm Ventures, LLC from 75% to 87.5%

Full summary

Radiopharm Theranostics Ltd's preliminary final report for the year ended 30 June 2026 highlights a substantial loss of $56,950,494, up from $38,342,457 the previous year. Revenue from contracts with customers fell by 23.8% to $2,767,888. The loss from ordinary activities after tax rose by 50.3% to $(55,149,150). Net assets decreased to $22,323,683 from $42,871,904 due to higher investment in research and development. The company increased its ownership in Radiopharm Ventures, LLC from 75% to 87.5%. Audited financial statements are expected by the end of September 2026.